LAUSR

Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J. & Roth, W. (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition, 36, 386–399. Glund, S., Stangier, J., Schmohl, M., Gansser, D., Norris, S., van Ryn, J., Lang, B., Ramael, S., Moschetti, V., Gruenenfelder, F., Reilly, P. & Kreuzer, J. (2015) Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet, 386, 680–690. Levy, J.H., Ageno, W., Chan, N.C., Crowther, M., Verhamme, P. & Weitz, J.I.; Subcommittee on Control of Anticoagulation. (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 14, 623–627. Peetermans, M., Pollack, C. Jr, Reilly, P., Liesenborghs, L., Jacquemin, M., Levy, J.H., Weitz, J.I. & Verhamme, P. (2016) Idarucizumab for dabigatran overdose. Clinical Toxicology, 54, 644– 646. Reilly, P.A., Lehr, T., Haertter, S., Connolly, S.J., Yusuf, S., Eikelboom, J.W., Ezekowitz, M.D., Nehmiz, G., Wang, S., Wallentin, L. & Investigators, R.E.-L.Y. (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). Journal of the American College of Cardiology, 63, 321–328. van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K.H., Wienen, W., Feuring, M. & Clemens, A. (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis, 103, 1116– 1127. Stangier, J., Rathgen, K., St€ahle, H., Gansser, D. & Roth, W. (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British Journal of Clinical Pharmacology, 64, 292–303.